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Abstract
Objective Assess the relationship between umbilical cord blood magnesium concentration and
level of delivery room resuscitation received by neonates.
Study design Secondary analysis of a controlled fetal neuroprotection trial that enrolled women at
imminent risk for delivery between 24 and 31 weeks’ gestation and randomly allocated them to
receive intravenous magnesium sulfate or placebo. The cohort included 1507 infants for whom
total cord blood magnesium concentration and delivery room resuscitation information were
available. Multivariable logistic regression was used to estimate the association between cord
blood magnesium concentration and highest level of delivery room resuscitation, using the
following hierarchy: none, oxygen only, bag-mask ventilation with oxygen, intubation or chest
compressions.
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Results—There was no relationship between cord blood magnesium and delivery room
resuscitation (odds ratio [OR] 0.92 for each 1.0 mEq/L increase in magnesium; 95% confidence
interval [CI]: 0.83-1.03). Maternal general anesthesia was associated with increased neonatal
resuscitation (OR 2.51; 95% CI: 1.72-3.68). Each 1-week increase in gestational age at birth was
associated with decreased neonatal resuscitation (OR 0.63; 95% CI: 0.60 – 0.66).
Conclusion—Cord blood magnesium concentration does not correlate with the level of delivery
room resuscitation of infants exposed to magnesium sulfate for fetal neuroprotection.
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Magnesium is implicated in numerous physiologic and pharmacologic roles including the
reduction of myometrial and other smooth muscle contractility, depression of CNS
irritability, stabilization of cellular membranes and interference with acetylcholine release at
the neuromuscular junction.(1-3) For decades, pregnant women have received magnesium
sulfate (MgSO4) for either tocolysis or the prevention of eclampsia. Recently, multiple
studies have demonstrated that antenatal treatment with MgSO4 reduces the risk of cerebral
palsy among children born preterm.(4-6)
Adverse effects may occur in women who become hypermagnesemic during MgSO4
treatment. These include muscular weakness, diminished deep tendon reflexes and
respiratory depression.(2) Similar adverse effects may occur in neonates exposed to MgSO4
antenatally. In clinical practice, infants whose mothers received MgSO4 for any indication
are thought to be at risk for respiratory depression, and thus an increased need for delivery
room resuscitation. For example, case reports suggest a relationship between fetal MgSO4
exposure and the need for resuscitation immediately after birth.(7, 8) To date, however,
hypothesized adverse effects on neonates have not been proven. Despite the lack of
definitive evidence linking fetal magnesium exposure and the need for resuscitation, the
American Academy of Pediatrics and American Heart Association supported Neonatal
Resuscitation Program (NRP) lists MgSO4 among maternally administered medications that
might depress respirations in the newborn.(9)
Our objective in this secondary analysis of the largest trial of magnesium sulfate for fetal
neuroprotection was to estimate the relationship between umbilical cord blood magnesium
concentration and the need for resuscitation of infants immediately after delivery. In the
primary analysis of the trial, there was no overall association between MgSO4 exposure and
increased delivery room resuscitation.(4) However, this finding does not preclude a
concentration-dependent effect. Therefore, in this investigation, we evaluated the association
between cord blood magnesium concentration and delivery room resuscitation.
METHODS
This was a secondary analysis of the Eunice Kennedy Shriver National Institute of Child
Health and Human Development Maternal Fetal Medicine Units (MFMU) Network trial of
MgSO4 for the prevention of cerebral palsy.(4) From December 1997 through May 2004,
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women at imminent risk for preterm delivery between 24 and 31 weeks’ gestation were
randomized to receive intravenous MgSO4 or placebo. Magnesium sulfate (or matching
placebo) was given to study participants intravenously as a 6 gram loading dose over 20
minutes followed by 2 grams infused each hour in minimal volume intravenous fluids. The
infusion could be increased to a maximum of 4 grams per hour at the discretion of the
physician and was continued for at least 12 hours if delivery did not occur. Retreatment with
the study drug was given for recurrence of labor or anticipated delivery unless criteria for
exclusion developed in the interim. The primary outcome was the composite of stillbirth or
death by 1 year corrected age or moderate or severe cerebral palsy at 2 years corrected age.
Details of the study are reported elsewhere.(4) Mother/neonate dyads included in the current
analysis were enrolled in the original trial and had both cord blood magnesium concentration
and delivery room resuscitation data recorded. Neonates who fulfilled these criteria were
included in this analysis irrespective of the mother's allocation to magnesium or placebo.
The institutional review board at each of the 20 participating centers approved participation
in the trial. All participants gave written informed consent before enrollment.
Trained, certified research nurses collected data prospectively and included information on
both maternal and neonatal characteristics, complications and outcomes. Data describing
other medications given during labor, including anesthetic agents and analgesics, were
abstracted from the mothers’ charts. Gestational age at entry to the trial was determined
according to a standard method predicated on the date of the last menstrual period and the
results of the earliest available ultrasound.(10) Umbilical cord blood was collected
immediately after delivery and serum was separated within 45 to 120 minutes following
collection. Samples were frozen within 12 hours from the time the blood was collected and
stored locally at -70° C until shipping to a central laboratory (Quest Diagnostics, Van Nuys,
California). Total magnesium was measured using the Olympus chemistry analyzer, valid
low= 0.4mEq/L (0.2mmol/L).
Neonatal delivery data recorded included the highest level of delivery room resuscitation
received by the infant. The hierarchy of this variable (from lowest to highest) was none,
followed by oxygen only, bag-mask ventilation with oxygen, intubation or chest
compressions. All infants, including those labeled with a resuscitation variable of “none,”
received standard delivery room care.(9)
Statistical analyses
Statistical analyses were performed using SAS® statistical software (SAS institute, Cary,
NC). The primary outcome was the highest level of delivery room resuscitation received by
the infant. The primary exposure was cord blood magnesium concentration. Generalized
estimating equations were used to account for the correlations between siblings of twin
pregnancies. Proportional odds models within this framework allowed for regression
analyses to measure the association between magnesium and the five-level ordinal
resuscitation variable (none, oxygen only, bag-mask ventilation, intubation or chest
compressions). These regression models were used for univariate analyses, as well as for
multivariable analyses that controlled for gestational age, administration of maternal
narcotics and general anesthesia. Odds ratios (OR; 95% Confidence Interval) were
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calculated for each of the predictor variables. Similar models were constructed with the
dichotomous outcome of none vs. any resuscitation using ordinary logistic regression.
RESULTS
In the parent study, 2444 fetuses were randomized at 20 sites between December 1997 and
May 2004. Of these, 924 were excluded from this secondary analysis because cord blood
was unavailable either because clinical staff were unable to obtain it or there was an
insufficient amount of blood available after other testing. There were 13 stillbirths. Our
study cohort comprised 1507 infants with both cord blood magnesium concentration and
delivery room resuscitation data. A total of 723 mothers (48.0%) were assigned to MgSO4
and 784 mothers (52.0%) were assigned to placebo. Neonates in the present analysis were of
more advanced gestational age, of higher birth weight and more often delivered vaginally
than neonates for whom cord blood magnesium concentration was not available (Table I).
The mean gestational age at delivery was 30.0 ± 2.9 weeks; only 28 (1.9%) infants were
delivered after 37 weeks.
Of the 1507 infants, 252 (16.7%) received no additional resuscitation (Table II). For infants
who received any form of resuscitation, oxygen only and intubation were the most common;
432 (28.7%) and 528 (35.0%) infants, respectively. Relatively few infants required chest
compressions, n=46 (3.1%). Decreasing birth weight and gestational age at birth were
associated with an increasing receipt of resuscitation. Infants who received chest
compressions had a mean birth weight of 1050g, whereas those who received oxygen and
those who did not receive any additional resuscitation had mean birth weights of 1660g and
1883g, respectively. The mean gestational age at birth decreased with increasing level of
resuscitation (p < 0.001). Infants who received intubation or chest compressions tended to
have lower 1- and 5-minute Apgar scores and greater exposure to general anesthesia.
Table III represents the univariate analysis of the highest level of resuscitation in relation to
cord blood magnesium concentration. The mean magnesium concentration for the cohort
was 2.05 ± 0.88 mEq/L which did not significantly differ across the highest level of
resuscitation recorded (p = 0.28). Of the 1507 infants, 51 (3.4%) had magnesium
concentrations greater than 4.0 mEq/L; only 6 (0.4%) had concentrations greater than 5.0
mEq/L. Additional (any) delivery room resuscitation was received by 45 (88.2%) of these 51
infants. The resuscitation received by the 6 infants with a magnesium concentration of >5.0
mEq/L included intubation (4), bag/mask (1) or oxygen (1).
We included cord blood magnesium concentration, gestational age at birth, administration of
maternal narcotics, and general anesthesia in a multivariable logistic regression analysis to
determine the association between the highest level of resuscitation (using the 5-level
ordinal model) and cord blood magnesium concentration (Table IV). Cord blood magnesium
concentration was not associated with an increased need for delivery room resuscitation (OR
0.92 for each 1.0 mEq/L increase in magnesium; 95% CI: 0.83-1.03). Maternal general
anesthesia was associated with increased delivery room resuscitation (OR 2.51; 95% CI:
1.72-3.68) but maternal administration of narcotics was not (OR 0.97; 95% CI: 0.80-1.19).
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For each 1-week increase in gestational age at birth there was decreased receipt of delivery
room resuscitation (OR 0.63; 95% CI: 0.60 – 0.66).
An additional regression analysis was performed with resuscitation as a dichotomous
variable, none vs. any, to again look for an association between the highest level of
resuscitation and cord blood magnesium concentration. This model similarly included
gestational age at birth, cord blood magnesium concentration, general anesthesia and
maternal narcotics. This model yielded identical findings to the 5-level ordinal model, with
no association between cord blood magnesium concentration and receipt of delivery room
resuscitation (data not shown).
DISCUSSION
In the setting of MgSO4 administration for neuroprotection in anticipated preterm birth, we
found no association between umbilical cord blood magnesium concentration and the receipt
of an increased level of delivery room resuscitation in newborn infants, after adjusting for
gestational age at birth and several intrapartum exposures. Exposure to general anesthesia
was associated with a greater degree of neonatal resuscitation, an association that has
previously been reported.(11-13) Not surprisingly, increasing gestational age at birth was
associated with decreased receipt of delivery room resuscitation, consistent with previous
reports.(13-15)
Previous studies appear to support our observation that cord blood concentrations of
magnesium do not predict the need for neonatal resuscitation. For example, Lipsitz and
English reported on 16 neonates with effects of hypermagnesemia, including mild
respiratory depression, hypotonia and hyporeflexia following maternal exposure to MgSO4
for preeclampsia.(16) However, they found no correlation between Apgar scores or other
clinical signs and cord blood magnesium concentration or need for resuscitation. In a case
controlled study, Riaz et al reported a non-statistically significant increase in delivery room
support, defined as bag-mask ventilation, in 26 MgSO4 exposed infants.(17) They reported
these infants more likely to be hypotonic and to have lower Apgar scores. However, there
was no association of these outcomes with cord blood magnesium concentration, maternal
magnesium concentration, or total dose or duration of maternal MgSO4 exposure. In the
parent trial for this secondary analysis, there was no statistically significant difference in
rates of generalized hypotonia or the composite outcome of intubation and chest
compressions among magnesium vs. placebo exposed infants.(4) Along with our results,
these studies suggest that fetal MgSO4 exposure does not have adverse effects on delivery
room resuscitation. Rather, the confounding circumstances that are associated with maternal
MgSO4 treatment (e.g., early gestational age) may increase the likelihood of respiratory
depression immediately after birth, thus leading to increased receipt of delivery room
resuscitation.
Published literature related to intrapartum magnesium sulfate exposure has primarily
addressed the neonate born to mothers with preeclampsia or eclampsia as the indication for
magnesium exposure.(17-19) Few studies have focused exclusively on the preterm infant,
and most have reported only Apgar scores or clinically subjective assessment scales as
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surrogate markers of the presumed impact of magnesium exposure on delivery room
resuscitation. Despite reports of the effects of magnesium exposure on tone, Apgars or
clinical assessment, none of these studies found a correlation between cord blood or serum
magnesium concentration and the degree of neonatal depression.
There are several strengths and limitations to our study. We included a large number of
infants. The magnesium concentration was measured at birth, and thus is the most accurate
reflection of fetal magnesium levels. Clinicians who were resuscitating the infant were
unaware of treatment assignment, and thus bias was limited. As for limitations, infants in
our study had relatively low levels of magnesium in the cord blood (mean 2.05 ± 0.88
mEq/L), compared with other studies with a range 1.8-11.5mg/dL (1.5mEq/L-9.6mEq/L).
(16-18, 20) Thus it is possible that very high concentrations of cord blood magnesium might
be associated with a greater need for resuscitation. Of the 1507 infants, 51 (3.4%) had
magnesium concentrations greater than 4.0 mEq/L and only 6 (0.4%) of these had
concentrations greater than 5.0 mEq/L, with the majority of these infants receiving
additional delivery room resuscitation. Thus, our analysis is not powered to look for an
association at higher concentrations. It is worth emphasizing, however, that antenatal
magnesium administration in the dose range utilized for neuroprotection rarely resulted in
high cord blood magnesium concentrations, so even if a subsequent association were found,
it would be applicable to only a small minority of infants exposed to magnesium sulfate for
neuroprotection.
We did not investigate other reported side effects of MgSO4 exposure, such as apnea/
hypoventilation following admission or delayed feeding tolerance or ileus. In addition, our
findings might not be applicable to term infants because our cohort was primarily composed
of preterm infants, with only 28 (1.9%) infants greater than 37 weeks gestation at delivery.
The threshold for delivery room intubation of extremely preterm infants (i.e. for surfactant
administration) might vary across sites, however these data were not collected as part of this
study.
In conclusion, we found no association between umbilical cord blood magnesium
concentration and receipt of delivery room resuscitation of infants. This finding should
motivate clinicians to further investigate an etiology for greater level of delivery room
resuscitation, and to consider other potential contributing causes for the need for
resuscitation. The findings of this analysis should allow providers to provide magnesium
sulfate for neuroprotection without the concern that it will lead to additional invasive
delivery room resuscitation measures.
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Table 1
Neonatal Characteristics and Intrapartum Care: Comparison of Those With and Without Available Cord Blood
Magnesium Concentration
Mg Concentration Not Available n=924 Mg Concentration Available n=1507 P-Value
Gestational age, wk
* 29.3 ± 3.4 30.0 ± 2.9 <0.001
Birth weight, g 1324 ± 615 1472 ± 539 <0.001
Birth weight, ≤ 1500g 633 (68.7) 828 (54.9) <0.001
Female 437 (47.3) 710 (47.1) 0.93
Mode of Delivery
Vaginal (1456) 502 (54.4) 954 (63.3) <0.001
Cesarean (973) 420 (45.6) 553 (36.7)
Race
African-American 400 (43.3) 645 (42.8) 0.74
Caucasian 330 (35.7) 580 (38.5)
Hispanic 176 (19.0) 245 (16.3)
Asian 4 (0.4) 16 (1.1)
Native American 1 (0.1) 2 (0.1)
Other 13 (1.4) 9 (1.3)
1-minute Apgar 6 (4-8) 7 (5-8) <0.001
1-minute Apgar <5 293 (31.9) 302 (20.1) <0.001
5-minute Apgar 8 (7-9) 8 (7-9) 0.09
5-minute Apgar <7 225 (24.5) 229 (15.2) <0.001
General Anesthesia 101 (12.5) 103 (7.3) <0.001
Maternal Narcotics 297 (36.7) 521 (37.1) 0.90
Twin Gestation 91 (11.1) 112 (8.0) <0.001
Data are presented as mean ± SD, n (%) or median (interquartile range)
*
Gestational age at delivery
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Table 3
Level of Resuscitation by Cord Blood Magnesium Concentration
Magnesium concentration (mEq/L)
Highest Level of Resuscitation Recorded





Intubation n=528 Chest Compressions n=46 Any n=1255
< 1.0, n=52 12 (23.1) 13 (25.0) 10 (19.2) 15 (28.9) 2 (3.9) 40 (76.9)
1.0 - <2.0, n=900 167 (18.6) 257 (28.6) 134 (14.9) 317 (35.2) 25 (2.8) 733 (81.4)
2.0 - <3.0, n=279 38 (13.6) 66 (23.7) 57 (20.4) 108 (38.7) 10 (3.6) 241 (86.4)
3.0 - <4.0, n=225 29 (12.9) 75 (33.3) 42 (18.7) 70 (31.1) 9 (4.0) 196 (87.1)
4.0 - <5.0, n=45 6 (13.3) 20 (44.4) 5 (11.1) 14 (31.1) 0 (0) 39 (86.7)
≥5.0, n=6 0 (0) 1 (16.7) 1 (16.7) 4 (66.7) 0 (0) 6 (100.0)
Mean Magnesium concentration
* 1.9 ±0.81 2.1 ±0.96 2.1 ±0.88 2.0 ±0.86 2.1 ±0.81 2.1 ±0.89
Data are presented as number (%) or mean ± standard deviation
*
Mean magnesium concentration did not differ across the highest level of resuscitation recorded, p=0.28






















Johnson et al. Page 13
Table 4
Multivariable Analysis of Risk for Delivery Room Resuscitation
*
Variable Odds Ratio 95% Confidence Interval
Magnesium 
** 0.92 0.83-1.03
General Anesthesia 2.51 1.72-3.68




Analysis of delivery room resuscitation as a 5-level ordinal variable and adjusted for magnesium, general anesthesia, maternal narcotics and
gestational age
**
For each 1.0mEq/L interval increase in cord magnesium concentration
***
For each 1-week increase in gestational age
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